Related Experiment Videos
[New treatment for orbital non-Hodgkin's lymphoma: 2 cases treated with rituximab]
L Benabid1, B Desablens, T Defossez
1Service d'Ophtalmologie, CHU d'Amiens, Centre Saint Victor, 354, Boulevard de Beauvillé, 80000 Amiens. leilan.benabid@laposte.net
Introduction:
Orbital non-Hodgkin's lymphoma is a rare tumor whose diagnosis is often difficult. Treatment of latent lymphoma have been changing because of progress in immunotherapy.
Observation:
We report two patients treated with rituximab (antibody anti-CD20). Two women, 50 and 59 years old, presented low-grade, IE-stage lymphoma. One was conjunctival MALToma, the other was orbitopalpebral, type A, of WFC classification, follicular, with small cells. Immunohistochemistry showed a diffused marking for Ac anti-CD20. Both patients received intravenous rituximab as a first treatment in December 2000, 375 mg/m2, four injections per week. We did not note any major undesirable effects. Both have been in complete remission for 4 years. These patients continue to be followed up.
Discussion:
Rituximab's efficacy has been proved mainly in follicular LMNH or in recurrent forms. The recurrence may be more frequent in MALT lymphoma. This medical treatment has low hematologic toxicity.
Conclusion:
Rituximab offers an alternative for low-grade lymphoma treatment that is well tolerated by the patient.